Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
22.38%
Operating Margin
11.89%
Net Margin
9.71%
Efficiency Metrics
Revenue per Expense Ratio
1.14
R&D as % of Revenue
2.60%
Earnings Quality
EBITDA Margin
19.62%
Income Tax Rate
17.57%
EPS
7.5400000000
Balance Sheet Analysis
Current Ratio
1.35
Cash Ratio
0.21
Working Capital
$905.00M
Debt to Equity
0.91
Debt to Assets
33.94%
Equity Ratio
37.30%
Cash Flow Analysis
Operating Cash Flow Ratio
14.92%
Free Cash Flow Ratio
5.87%
CapEx to Revenue
9.04%
Dividends Paid
$376.00M
Stock Buybacks
$150.00M
Total Shareholder Returns
$526.00M
Cash Position Change
11.16%
Key Takeaways (2023 FY)
Revenue declined by 12.948960302457%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased dividend payments by 13.58%
Detailed Growth Metrics
Core Performance
Revenue
-12.95%
Net Income
12.74%
EPS
28.89%
Operating Income
-12.68%
Operational Efficiency
R&D Expenses
-9.47%
SG&A Expenses
0.14%
Operating Cash Flow
40.92%
Free Cash Flow
54.13%
Balance Sheet Health
Assets
-0.23%
Debt
-3.59%
Book Value per Share
21.56%
Inventory
-11.14%
Shareholder Returns
Dividends per Share
13.58%
Shares Outstanding
-13.11%
Long Term Trends
3Y Revenue/Share
24.19%
5Y Revenue/Share
8.02%
3Y Dividend/Share
19.99%
5Y Dividend/Share
40.77%